Early clinical, histological, and immunohistochemical findings in suspected acute graft-versus-host disease and their association with patient outcomes.

Abstract

Pediatric DermatologyVolume 38, Issue 1 p. 342-343 CORRIGENDUMFree Access Early clinical, histological, and immunohistochemical findings in suspected acute graft-versus-host disease and their association with patient outcomes This article corrects the following: Early clinical, histological, and immunohistochemical findings in suspected acute graft-versus-host disease and their association with patient outcomes Maria Teresa García-Romero MD, MPH, Marimar Sáez-de-Ocariz MD, Carolina Hernández-Zepeda MD, Montserrat Reyes MD, Silvestre García de la Puente MD, Cecilia Ridaura-Sanz MD, Gerardo López-Hernández MD, Alberto Olaya-Vargas MD, Volume 37Issue 4Pediatric Dermatology pages: 613-621 First Published online: April 3, 2020 First published: 25 February 2021 https://doi.org/10.1111/pde.14451Citations: 1AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat In the article by Maria Teresa García-Romero et al,1 a section titled “Primary diagnosis” in Table 2 “Diagnosis” has been removed because it is incorrectly included in previous version. The correct version of Table 2 is set as follows. Table 2. Clinical and demographic characteristics of our patients and donors N = 42 Gender Female 15 (35.7%) Male 27 (64.3%) Age at diagnosis, median (min-max) 7.5 y (0-17 y) Age at HSCT, median (min-max) 9.5 y (0-18 y) Age at HSCT ≥ 10 y 21 (50%) Diagnosis Acute lymphoblastic or myelocytic leukemia 26 (61.9%) Chronic myeloid leukemia 2 (4.8%) Immunodeficiency 6 (14.3%) Other nonmalignant disease (Griscelli syndrome, aplastic anemia, adrenoleukodystrophy, etc) 8 (19%) Source of stem cells Peripheral blood 30 (71.4%) Umbilical cord 8 (19%) Bone marrow 4 (9.5%) Type of donor Related 32 (76.2%) Unrelated 10 (23.8%) HLA match Fully matched 18 (42.9%) Mismatched (at least 1 /10) 10 (23.8%) Haploidentical 14 (33.3%) Discordant gender between donor and recipient Females with female donor 23 (54.8%) Females with male donor 9 (21.4%) Males with female donor 4 (9.5%) Males with male donor 19 (45.2%) Unknown (umbilical cord blood) 3 (7.1%) Previous pregnancies of female donors (n = 28) None 17 (40.5%) One 3 (7.1%) Two 3 (7.1%) Three 4 (19.5%) Four 1 (2.4%) Time between HSCT and manifestations, median (min-max) 51 d (2-3221) Patients who had more than one graft 6 (14.3%) Abbreviations: HLA, Human leukocyte antigen; HSCT, Hematopoietic stem cell transplant. REFERENCE 1García-Romero MT, Sáez-de-Ocariz M, Hernández-Zepeda C, et al. Early clinical, histological, and immunohistochemical findings in suspected acute graft-versus-host disease and their association with patient outcomes. Pediatr Dermatol. 2020; 37: 613- 621. https://doi.org/10.1111/pde.14152Wiley Online LibraryPubMedWeb of Science®Google Scholar Citing Literature Volume38, Issue1January/February 2021Pages 342-343 ReferencesRelatedInformation